Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono and Newron expand drug development collaboration

Merck Serono and Newron expand drug development collaboration

1st April 2011

Merck Serono has announced an expansion of its collaborative relationship with Italy-based Newron Pharmaceuticals.

The new agreement will grant Newron a development license for two of Merck Serono's clinical-stage compounds, pruvanserin and sarizotan, which modulate the activity of neurotransmitters in the brain to treat central nervous system diseases.

Newron will be responsible for conducting proof of concept trials for the drugs and will be given a co-development option should Merck Serono choose to buy the compounds back once the studies are complete.

This new project builds upon their existing alliance, under which the companies are jointly developing a new Parkinson's disease therapy called safinamide.

Dr Bernhard Kirschbaum, executive vice-president for global research and development at Merck Serono, said: "We believe that this expanded collaboration will leverage Newron's strong expertise in the early-stage development of compounds targeting central nervous system indications."

Earlier this week, it was announced that Merck Serono is applying to the European Medicines Agency for its drug Erbitux to be approved as a treatment for non-small cell lung cancer.ADNFCR-8000103-ID-800483910-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.